The third day of the ASCO conference showcased a notable breakthrough in pancreatic cancer treatment, particularly highlighting the achievements of RevMed.
In contrast, Akeso and Summit experienced setbacks, raising concerns about their current trajectories in the competitive landscape of cancer therapies.
Additionally, a new approach to immunotherapy was introduced, suggesting potential shifts in treatment paradigms moving forward.